Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

BACKGROUND: T cell-based immunotherapies using chimeric antigen receptors (CAR) or bispecific antibodies (BsAb) have produced impressive responses in hematological malignancies. However, major hurdles remained, including cytokine release syndrome, neurotoxicity, on-target off-tumor effects, reliance...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Park, Jeong A, Santich, Brian H, Xu, Hong, Lum, Lawrence G, Cheung, Nai-Kong V
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2021
Konular:
Immune Cell Therapies and Immune Cell Engineering
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8126293/
https://ncbi.nlm.nih.gov/pubmed/33986124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002222
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller